Synchrony Financial Shares Face Scrutiny as Multi-Year Run Cools

Synchrony Financial shares have encountered recent downward pressure, trading at US$71.70 after dropping approximately 9.7% over the past 90 days. Despite that retreat, the consumer financial services company has delivered a 3-year total shareholder return of about 150.4% or 150.5% and a 5-year return of about 61.5%. Alongside the pullback, the company recently rolled out a partnership with Clarus Technology to integrate payment insights and real-time insurance workflows into veterinary practices, supplementing ongoing health and wellness initiatives through CareCredit integrations and Stripe.

The recent drop has turned market attention to Synchrony Financial's earnings metrics. According to analysis from Simply Wall St, the lender trades at roughly 6.9x earnings, placing it below the broader consumer finance industry average of 8.3x and peer multiples around 15.9x. MarketBeat also reported a price-to-earnings ratio of 7.64. Analysts and valuation models note that these multiples may suggest the stock screens as undervalued, though consumer credit performance, funding expenses, and credit losses remain key factors influencing that discount.

On October 20, Synchrony Financial reported third-quarter 2026 earnings that brought mixed reactions. Adjusted earnings per share reached $2.68, topping analyst projections of $2.42, while revenue landed at $3.8 billion to $3.82 billion. Revenue was flat year over year, and the company missed consensus expectations on tangible book value per share. Net interest income arrived in line with projections, and the firm reported a return on equity of 22.26% alongside a net margin of 14.59%.

Wall Street coverage remains generally tilted toward positive ratings, though targets and opinions vary. A consensus tracked by Barchart shows a Moderate Buy rating across 22 analysts, with a mean price target of $86.35 and a Street high of $103.00. MarketBeat similarly notes a Moderate Buy consensus with an average target of $87.78. Meanwhile, UBS Group lowered its price target to $80.00 with a neutral or hold view, and Evercore reduced its stance from outperform to hold with a $78.00 price target.

Capital distributions continue alongside the lower valuation. The company declared a quarterly dividend of $0.34 per share, payable on November 16 to shareholders of record on November 5. Analysts on average project full-year diluted earnings per share to climb 1.8% to $9.59.